Intravascular Follistatin gene delivery improves glycemic control in a mouse model of type 2 diabetes
Jonathan R Davey, Emma Estevez, Rachel E Thomson, Martin Whitham, Kevin I Watt, Adam Hagg, Hongwei Qian, Darren C Henstridge, Helen Ludlow, Mark P Hedger, Sean L McGee, Melinda T Coughlan, Mark A Febbraio, Paul Gregorevic
FASEB JOURNAL | WILEY | Published : 2020
Type 2 diabetes (T2D) manifests from inadequate glucose control due to insulin resistance, hypoinsulinemia, and deteriorating pancreatic β-cell function. The pro-inflammatory factor Activin has been implicated as a positive correlate of severity in T2D patients, and as a negative regulator of glucose uptake by skeletal muscle, and of pancreatic β-cell phenotype in mice. Accordingly, we sought to determine whether intervention with the Activin antagonist Follistatin can ameliorate the diabetic pathology. Here, we report that an intravenous Follistatin gene delivery intervention with tropism for striated muscle reduced the serum concentrations of Activin B and improved glycemic control in the ..View full abstract
Related Projects (2)
USING GENE DELIVERY TECHNOLOGIES TO DEFINE NOVEL MECHANISMS OF SKELETAL MUSCLE ADAPTATION, AND DEVELOP MUSCLE-DIRECTED INTERVENTIONS FOR FRAILTY AND SERIOUS ILLNESS
The focus of my research is to investigate the cellular mechanisms underlying regulation of skeletal muscle size and function in health and ..
Awarded by National Health and Medical Research Council